Intervention Review

You have free access to this content

Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas

  1. Magali Lecavalier-Barsoum1,
  2. Harvey Quon2,
  3. Bassam Abdulkarim3,*

Editorial Group: Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group

Published Online: 15 MAY 2014

Assessed as up-to-date: 21 MAR 2014

DOI: 10.1002/14651858.CD007104.pub2


How to Cite

Lecavalier-Barsoum M, Quon H, Abdulkarim B. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database of Systematic Reviews 2014, Issue 5. Art. No.: CD007104. DOI: 10.1002/14651858.CD007104.pub2.

Author Information

  1. 1

    McGill University Health Centre, Radiation Therapy, Montreal, QC, Canada

  2. 2

    CancerCare Manitoba, Radiation Oncology, Winnipeg, MB, Canada

  3. 3

    Montreal General Hospital, Department of Oncology; Director, Division of Radiation Oncology; McGill University, Montréal, QC, Canada

*Bassam Abdulkarim, Department of Oncology; Director, Division of Radiation Oncology; McGill University, Montreal General Hospital, Department of Radiation Oncology, D5.120, 1650 Avenue Cedar, Montréal, QC, H3G 1A4, Canada. bassam.abdulkarim@mcgill.ca.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 15 MAY 2014

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. Additional references
  3. References to other published versions of this review
Cairncross 2006 {published data only}
  • Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology 2006;24(18):2707-14.
  • Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology 2013;31:337-43.
  • Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology 2014;32(8):783-90.
  • Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology 2008;18:360-9.
NOA-04 2009 {published data only}
  • Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of Clinical Oncology 2009;27(35):5874-80.
van den Bent 2006 {published data only}
  • Idbaih A, Dalmasso C, Kouwenhoven M, Jeuken J, Carpentier C, Gorlia T, et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-oncology 2011;103:221-30.
  • Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology 2009;11:737-46.
  • Mauer ME, Taphoorn MJ, Bottomley A, Coens C, Efficace F, Sanson M, et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. Journal of Clinical Oncology 2007;25:5731-37.
  • Mokhtari K, Ducray F, Kros JM, Gorlia T, Idbaih A, Taphoorn M, et al. Alpha internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer 2011;117:3014-26.
  • van den Ben MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology 2013;31:344-50.
  • van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology 2006;24(18):2715-22.
  • van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research 2010;16:1597-604.
  • van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo CR, Hegi M, Jeuken JW, et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology 2009;27:5881-6.
  • van den Bent MJ, Gravendeel LA, Gorlia T, Kros JM, Lapre L, Wesseling P, et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clinical Cancer Research 2011;17:7148-55.

Additional references

  1. References to studies included in this review
  2. Additional references
  3. References to other published versions of this review
Balss 2008
Boots-Sprenger 2013
  • Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Modern Pathology 2013;26(7):922-9.
Cairncross 1994
  • Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 1994;12(10):2013-21.
Cairncross 1998
  • Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Journal of the National Cancer Institute 1998;90(19):1473-9.
Camelo-Piragua 2010
  • Camelo-Piragua S, Jansen M, Ganguly A, Kim JC, Louis DN, Nutt CL. Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathologica 2010;119:509-11.
CBTRUS 2009
  • Central Brain Tumor Registry of the United States. Primary brain tumors in the United States statistical report, 2005-2009. Neuro-oncology 2009; Vol. 14 Suppl 5:v1-49.
Hartmann 2009
  • Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica 2009;118:469-74.
Higgins 2011
Ichimura 2009
  • Ichimura K, Pearson DM, Kocialkowski S, Bäcklund LM, Chan R, Jones DT, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncology 2009;11:341-7.
Kloosterhof 2011
  • Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ. Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?. The lancet oncology 2011;12:83-91.
Kouwenhoven 2009
  • Kouwenhoven MC, Gorlia T, Kros JM, Ibdaih A, Brandes AA, Bromberg JE, et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology 2009;11:737-46.
Laffaire 2011
  • Laffaire J, Everhard S, Idbaih A, Crinière E, Marie Y, de Reyniès A, et al. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro-oncology 2011;13:84-98.
Lassman 2011
  • Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-oncology 2011;13:649-59.
Li 2012
  • Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro-oncology 2012;14:109-16.
NCT00626990
  • NCT00626990. Radiation therapy with or without temozolomide in treating patients with anaplastic glioma. clinicaltrials.gov/ct2/show/NCT00626990 (accessed 13 May 2014).
NCT00887146
  • NCT00887146. Radiation therapy with concomitant and adjuvant temozolomide or radiation therapy with adjuvant PCV or temozolomide alone in treating patients with anaplastic glioma. clinicaltrials.gov/show/NCT00887146 (accessed 13 May 2014).
Parmar 1998
Parsons 2008
Smith 2000
  • Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. Journal of Clinical Oncology 2000;18(3):636-45.
Sonoda 2009
Stupp 2005
  • Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine 2005;352:987-96.
van den Bent 2003
Watanabe 2009
Yan 2009

References to other published versions of this review

  1. References to studies included in this review
  2. Additional references
  3. References to other published versions of this review
Quon 2008